Applications of gene transfer to cellular immunotherapy

Surgical Oncology Clinics of North America

Volumn 11, Issue 3, 2002, Pages 621-643

  Terando, Alicia ^a   Chang, Alfred E ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRIMER; DNA; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 18; MELAN A;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN SPECIFICITY; CANCER CHEMOTHERAPY; CELL SPECIFICITY; CELLULAR IMMUNITY; CLINICAL RESEARCH; CULTURE OPTIMIZATION; DENDRITIC CELL; DISEASE MODEL; DNA MODIFICATION; DRUG EFFICACY; EFFECTOR CELL; ERADICATION THERAPY; GENE THERAPY; GENE TRANSFER; GENETIC MANIPULATION; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOREACTIVITY; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; MICROSCOPIC ANATOMY; MINIMAL RESIDUAL DISEASE; REGULATORY MECHANISM; REVIEW; STEM CELL TRANSPLANTATION; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TISSUE SPECIFICITY;

ADENOVIRIDAE; ANIMALS; CANCER VACCINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; STEM CELLS;

EID: 0036660814     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1055-3207(02)00024-8     Document Type: Review

References (87)

1. Eglitis MA, Anderson WF. Retroviral vectors for introduction of genes into mammalian cells. Biotechniques 1988;6:608-14.
2. Miller DG, Adam MA, Miller AD. Gene transfer by retrovirus vectors occurs only in cells that are actively replicating at the time of infection. Mol Cell Biol 1990;10:4239-42.
3. Donahue RE, Kessler SW, Bodine D, et al. Helper virus induced T cell lymphoma in nonhuman primates after retroviral mediated gene transfer. J Exp Med 1992;176:1125-35.
4. Berkner KL. Development of adenovirus vectors for the expression of heterologous genes. Biotechniques 1988;6:616-29.
5. Brody SL, Crystal RG. Adenovirus-mediated in vivo gene transfer. Ann NY Acad Sci 1994;716:90-101.
6. Kotin RM, Siniscalco M, Samulski RJ, et al. Site-specific integration by adeno-associated virus. Proc Natl Acad Sci USA 1990;87:2211-15.
7. Felgner PL, Gadek TR, Holm M, et al. Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987;84:7413-17.
8. Nabel EG, Yang Z, Muller D, et al. Safety and toxicity of catheter gene delivery to the pulmonary vasculature in a patient with metastatic melanoma. Hum Gene Ther 1994;5:1089-94.
9. Nabel GJ, Gordon D, Bishop DK, et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-Liposome complexes. Proc Natl Acad Sci USA 1996;93:15388-93.
10. Nabel GJ, Nabel EG, Yang Z-Y, et al. Direct gene transfer with DNA-liposome complexes in melanoma: Expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993;90:11307-11.
11. Wagner E, Plank C, Zarloukal K, et al. Influenza virus hemagglutinin HA-2 N-terminal fusogenic peptides augment gene transfer by transferrin-polylysine-DNA complexes: Toward a synthetic virus-like gene transfer vehicle. Proc Natl Acad Sci USA 1992;89:7934-38.
12. Wagner E, Zatloukal K, Cotten M, et al. Coupling of adenovirus to transferrin-polylysine/DNA complexes greatly enhances receptor-mediated gene delivery and expression of transfected genes. Proc Natl Acad Sci USA 1992;89:6099-103.
13. Wu GY, Wilson JM, Shalaby F, et al. Receptor-mediated gene delivery in vivo: Partial correction of genetic analbuminemia in nagase rats. J Biol Chem 1991;266:14338-42.
14. Kukowska-Latallo JF, Bielinska AU, Johnson J, et al. Efficient transfer of genetic material into mammalian cells using starburst polyamidoamine dendrimers. Proc Natl Acad Sci USA 1996;93:4897-902.
15. Kukowska-Latallo JF, Raczka E, Quintana A, et al. Intravascular and endobronchial DNA delivery to murine lung tissue using a novel, nonviral vector. Hum Gene Ther 2000;11:1385-95.
16. Wang Y, Boros P, Liu J, et al. DNA/Dendrimer complexes mediate gene transfer into murine cardiac transplants ex vivo. Molecular Therapy 2000;2:602-8.
17. Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973;52:456-67.
18. Andreason GL, Evans GA. Introduction and expression of DNA molecules in eukaryotic cells by electroporation. Biotechniques 1988;6:650-60.
19. Kishida T, Asada H, Satoh E, et al. In vivo electroporation-mediated transfer of interleukin-12 and interleukin-18 genes induces significant antitumor effects against melanoma in mice. Gene Ther 2001;8:1234-40.
20. Lohr F, Lo DY, Zaharoff DA, et al. Effective tumor therapy with plasmid-encoded cytokines combined with in vivo electroporation. Cancer Res 2001;61:3281-84.
21. Tamura T, Nishi T, Goto T, et al. Intratumoral delivery of interleukin 12 expression plasmids with in vivo electroporation is effective for colon and renal cancer. Hum Gene Ther 2001;12:1265-76.
22. Chang AE, Tanigawa K, Turner JG, et al. Use of gene gun for genetic immunotherapy: In vitro and in vivo methods. In: Nickoloff BJ, editor. Melanoma: Methods and Protocols. Totawa, NJ: Humana Press Inc.; 2001. p. 223-40.
23. Woffendin C, Yang ZY, Udaykumar, et al. Nonviral and viral delivery of a human immunodeficiency virus protective gene into primary human T-cells. Proc Natl Acad Sci USA 1994;91:11581-85.
24. Yang N-S, Burkholder J, Roberts B, et al. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc Natl Acad Sci USA 1990;87: 9568-72.
25. Tan J, Yang NS, Turner JG, et al. Interleukin-12 cDNA skin transfection potentiates human papillomavirus E6 DNA vaccine-induced antitumor immune response. Cancer Gene Ther 1999;6:331-39.
26. Larregina AT, Watkins SC, Erdos G, et al. Direct transfection and activation of human cutaneous dendritic cells. Gene Ther 2001;8:608-17.
27. Miller AR, McBride WH, Hunt K, et al. Cytokine-mediated gene therapy for cancer. Ann Surg Oncol 1994;1:436-50.
28. Spiess PJ, Yang JC, Rosenberg SA. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J Natl Cancer Inst 1987;79:1067-75.
29. Restifo NP, Speiss PJ, Karp SE, et al. A nonimmunogenic sarcoma transduced with the cDNA for interferon y elicits CD8+ T-cells against the wild-type tumor: Correlation with antigen presentation capability. J Exp Med 1992;175:1423-31.
30. Marincola FM, Ettinghausen S, Cohen PA, et al. Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-alpha. J Immunol 1994;152:3500-13.
31. Mulders P, Tso C-L, Pang S, et al. Adenovirus-mediated interleukin-2 production by tumors induces growth of cytotoxic tumor-infiltrating lymphocytes against human renal cell carcinoma. J Immunother 1998;21:170-80.
32. Lefor AT, Fabian DF. Enhanced cytolytic activity of tumor infiltrating lymphocytes (TILs) derived from an ICAM-1 transfected tumor in a murine model. J Surg Res 1998;75:49-53.
33. Plautz GE, Yang Z-Y, Wu B-Y, et al. Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 1993;90:4645-49.
34. Gleich LL, Gluckman JL, Nemunaitis J, et al. Clinical experience with HLA-B7 plasmid DNA/lipid complex in advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2001;127:775-79.
35. Rini BI, Selk LM, Vogelzang NJ. Phase I study of direct intralesional gene transfer of HLA-B7 into metastatic renal carcinoma lesions. Clin Cancer Res 1999;5:2766-72.
36. Stopeck AT, Jones A, Hersh EM, et al. Phase II study of direct intralesional gene transfer of Allovectin-7, an HLA-B7/β2-Microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin Cancer Res 2001;7:2285-91.
37. Galanis E, Hersh EM, Stopeck AT, et al. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: Phase I/II experience. J Clin Oncol 1999;17:3313-23.
38. Chang AE, Aruga A, Cameron MH, et al. Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 1997;15:796-807.
39. Chang AE, Yoshizawa H, Sakai K, et al. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro. Cancer Res 1993;53:1043-50.
40. Yoshizawa H, Chang AE, Shu S. Specific adoptive immunotherapy mediated by tumor-draining lymph node cells sequentially activated with anti-CD3 and IL-2. J Immunol 1991;147:729-37.
41. Yoshizawa H, Sakai K, Chang AE, et al. Activation by Anti-CD-3 of tumor-draining lymph node cells for specific adoptive immunotherapy. Cell Immunol 1991;134:473-79.
42. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-43.
43. Arca MJ, Krauss JC, Aruga A, et al. Therapeutic efficacy of T-cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Cancer Gene Ther 1996;3:39-47.
44. Arca MJ, Krauss JC, Strome SE, et al. Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes. Cancer Immunol Immunother 1996;42:237-45.
45. Chang AE, Sondak VK, Bishop DK, et al. Adoptive immunotherapy of cancer with activated lymph node cells primed in vivo with autologous tumor cells transduced with the GM-CSF gene. Hum Gene Ther 1996;7:773-92.
46. Chang AE, Li Q, Bishop K, et al. Immunogenetic therapy of human melanoma utilizing autologous tumor cells transduced to secrete granulocyte-macrophage colony-stimulating factor. Hum Gene Ther 2000;11:839-50.
47. Tanigawa K, Yu H, Sun T, et al. Gene gun application in the generation of effector T-cells for adoptive immunotherapy. Cancer Immunol Immunother 2000;48:635-43.
48. Mazzolini G, Qian C, Narvaiza I, et al. Adenoviral gene transfer of interleukin-12 into tumors synergizes with adoptive T cell therapy both at the induction and effector level. Hum Gene Ther 2000;11:113-25.
49. Griffith KD, Read EJ, Carrasquillo JA, et al. In vivo distribution of adoptively transferred Indium-111-labelled tumor infiltrating lymphocytes and peripheral blood lymphocytes in patients with metastatic melanoma. J Natl Cancer Inst 1989;81:1709-17.
50. Hwu P, Schwarz S, Cowherd R, et al. Tumor infiltrating lymphocytes (TIL) transduced with the TNF alpha cDNA: Evidency for partial expression blockade at both the transcriptional and post translation levels [abstract]. Proceedings of the Annual Meeting of the American Association for Cancer Research. 1992. p. 832.
51. Hwu P, Yannelli J, Kriegler M, et al. Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-α c DNA for the gene therapy of cancer in humans. J Immunol 1993;150:4104-15.
52. Nakamura Y, Wakimoto H, Abe J, et al. Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin 2. Cancer Res 1994;54:5757-60.
53. Abe J, Wakimoto H, Tsunoda R, et al. In vivo antitumor effect of cytotoxic T lymphocytes engineered to produce interferon-y by adenovirus-mediated genetic transduction. Biochem Biophys Res Commun 1996;218:164-70.
54. Eshhar Z, Waks T, Gross G, et al. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-blinding domains and the γ or ζ subunits of the immunoglobulin and T cell receptors. Proc Natl Acad Sci USA 1993;90:720-24.
55. Moritz D, Wels W, Mattern J, et al. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci USA 1994;91:4318-22.
56. Hwu P, Shafer GE, Treisman J, et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor γ chain. J Exp Med 1993;178:361-66.
57. Hwu P, Yang JC, Cowherd R, et al. In vivo antitumor activity of T-cells redirected with chimeric antibody/T cell receptor genes. Cancer Res 1995;55:3369-73.
58. Rivoltini L, Kawakami Y, Sakaguchi K, et al. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1. J Immunol 1995;154:2257-65.
59. Topalian SL, Rivoltini L, Mancini M, et al. Human CD4+ T-cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 1994;91:9461-65.
60. Traversari C, van der Bruggen P, Luescher IF, et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992;176:1453-57.
61. Zakut R, Topalian SL, Kawakami Y, et al. Differential expression of MAGE-1, -2, and -3 messenger RNA in transformed and normal human cell lines. Cancer Res 1993;53:5-8.
62. Cole DJ, Weil DP, Shilyansky J, et al. Characterization of the functional specificity of a cloned T cell receptor heterodimer recognizing the MART-1 melanoma antigen. Cancer Res 1995;55:748-52.
63. Clay TM, Custer MC, Sachs J, et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol 1999;163:507-13.
64. Parker LL, Do MT, Westwood JA, et al. Expansion and characterization of T-cells transduced with a chimeric receptor against ovarian cancer. Hum Gene Ther 2000;11:2377-87.
65. Rossig C, Bollard CM, Nuchtern JG, et al. Targeting of GD2-positive tumor cells by human T lymphocytes engineered to express chimeric T cell receptor genes. Int J Cancer 2001;94:228-36.
66. Darcy PK, Haynes NM, Snook MB, et al. Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL. J Immunol 2000;164:3705-12.
67. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-44.
68. Bagnis C, Gravis G, Imbert A-M, et al. Retroviral transfer of the nlsLacZ gene into human CD34+ cell populations and into TF-1 cells: Future prospects in gene therapy. Hum Gene Ther 1994;5:1325-33.
69. Lu L, Xiao M, Clapp DW, et al. High efficiency retroviral mediated gene transduction into single isolated immature and replatable CD34+ hematopoietic stem/progenitor cells from human umbilical cord blood. J Exp Med 1993;178:2089-96.
70. Khouri IF, Deisseroth AB. Genetic modification of hematopoietic stem cells for therapy of solid tumors and hematopoietic neoplasms. In: Levitt D, Merterlsmann R, editors. Hematopoietic Stem Cells: Biology and Therapeutic Applications. New York: Marcel Dekker; 1995. p. 219-27.
71. Ward M, Richardson C, Pioli P, et al. Transfer and expression of the human multiple drug resistance gene in human CD34+ cells. Blood 1994;84:1408-14.
72. Moscow JA, Huang H, Carter C, et al. Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy. Blood 1999;94:52-61.
73. Hege KM, Cooke KS, Finer MH, et al. Systemic T cell-independent tumor immunity after transplantation of universal receptor-modified bone marrow into SCID mice. J Exp Med 1996;184:2261-69.
74. Wang G, Chopra RK, Royal RE, et al. A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-γ chain chimeric receptor gene recognizing a human ovarian cancer antigen. Nat Med 1998;4:168-72.
75. Romani N, Reider D, Heuer M, et al. Generation of mature dendritic cells from human blood: An improved method with special regard to clinical applicability. J Immunol Methods 1996;196:137-51.
76. Celluzzi CM, Mayordomo JI, Storkus WJ, et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996;183:283-87.
77. Cohen PA, Cohen PJ, Rosenberg SA, et al. CD4+ T-cells from mice immunized to syngeneic sarcomas recognize distinct, non-shared tumor antigens. Cancer Res 1994;54:1055-58.
78. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-8.
79. Henderson RA, Nimgaonkar MT, Watkins SC, et al. Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen Mucin (MUC-1). Cancer Res 1996;56:3763-70.
80. Kaplan JM, Yu Q, Piraino ST, et al. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J Immunol 1999;163:699-707.
81. Specht JM, Wang G, Do MT, et al. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J Exp Med 1997;186:1213-21.
82. Reeves ME, Royal RE, Lam JS, et al. Retroviral transduction of human dendritic cells with a tumor-associated antigen gene. Cancer Res 1996;56:5672-77.
83. Ribas A, Butterfield LH, McBride W, et al. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res 1997;57:2865-69.
84. Furumoto K, Arii S, Yamasaki S, et al. Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses. Int J Cancer 2000;87:665-72.
85. Akiyama Y, Watanabe M, Maruyama K, et al. Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines. Gene Ther 2000;7:2113-21.
86. Kirk CJ, Hartigan-O'Connor D, Mule JJ. The dynamics of the T-cell antitumor response: Chemokine-secreting dendritic cells can prime tumor-reactive T-cells extranodally. Cancer Res 2001;61:8794-802.
87. Kirk CJ, Hartigan-O'Connor D, Nickoloff BJ, et al. T cell-dependent anti-tumor immunity mediated by secondary lymphoid tissue chemokine. Cancer Res 2001;61:2062-70.